FDA to convene expert panel to review restrictions on popular peptides

The U.S. Food and Drug Administration (FDA) has announced it will convene the Pharmacy Compounding Advisory Committee on July 23 and 24, 2026. The panel will consider whether to allow licensed compounding pharmacies to manufacture several popular peptides that were restricted in 2023. These short chains of amino acids, which serve as essential biological building blocks, have seen a surge in popularity for wellness and performance, though they have faced regulatory hurdles due to safety concerns.

Peptides under review and previous restrictions

The upcoming review marks a potential reversal for a group of substances the FDA previously barred from compounding, citing risks related to immunogenicity, toxicity, and potential impurities. The specific peptides scheduled for discussion in July include:

• BPC 157: Often sought for ulcerative colitis and tissue repair.

• KPV: Studied for wound healing and inflammatory conditions.

• TB 500: Used by many for injury recovery.

• MOTS c: Marketed for obesity and bone health.

• Semax and Epitalon: Linked to cognitive and anti aging research.

• Emideltide (DSIP): Investigated for its role in sleep regulation.

Regulatory and political context

The move to re evaluate these substances comes amid a shift in health policy priorities. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly expressed support for expanding access to peptides, arguing that bringing them from the “gray market” to regulated ethical suppliers would improve patient safety. He has noted that making these compounds available through compounding pharmacies could shift demand away from illicit or unregulated sources.

Industry and patient impact

If the committee recommends including these substances on the 503A bulks list, it would allow compounding pharmacies to legally prepare customized versions of these peptides for individual patients. Currently, the Alliance for Pharmacy Compounding notes that pharmacies are facing high demand from patients and prescribers but are legally restricted from fulfilling those requests.

The FDA is also planning a secondary meeting to be held by February 2027 to review an additional five peptides, including GHK Cu. This phased approach indicates a broader effort by the agency to reassess the regulatory landscape for peptide therapies while balancing safety data with growing consumer and clinical interest.

---

---

Related Topics and Keywords

FDA, peptide review, peptides